• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    Solid pharmaceutical dosage form for the release of nicotine in the oral cavity comprising a core encapsulated by at least one film coating, wherein the core comprises nicotine and wherein the film coating comprises at least one film-forming polymer and at least one component for reduction of one or more organoleptically disturbing sensations, and where the at least one film coating is devoid of nicotine and devoid of buffer.
    公开号:AU2013206983A1
    申请号:U2013206983
    申请日:2013-01-07
    公开日:2014-07-03
    发明作者:Andreas Hugerth；Katarina Lindell；Fredrik Nicklasson；Kristina Thyresson
    申请人:McNeil AB；
    IPC主号:A61K9-28
    专利说明:
    WO 2013/103318 PCT/SE2013/050005 1 SOLID NICOTINE-COMPRISING DOSAGE FORM WITH REDUCED ORGANOLEPTIC DISTURBANCE Description Technical field The present invention relates to solid pharmaceutical dosage forms intended for s release of nicotine in the oral cavity, such dosage forms being provided with means for reducing one or more organoleptically disturbing sensations. Background of the invention Tobacco dependence and reduction thereof is a desirable goal. In recent years, with the recognition of the harmful effects of tobacco smoking, there have been 10 numerous campaigns and programs by governmental agencies and various health groups and other interested organisations to disseminate information about the adverse health effects resulting from tobacco smoking. Moreover, and as a result of this recognition of the harmful effects, there have been many programs directed to attempts in reducing smoking incidence. 15 Nicotine is an organic compound and is the principal alkaloid of tobacco. Nicotine is the chief addictive ingredient in the tobacco used in cigarettes, cigars, snuff and the like. Nicotine is also an addictive drug, and smokers characteristically display a strong tendency to relapse after having successfully stopped smoking for a time. Nicotine is the world's second most used drug, after caffeine from coffee and tea. 20 The main problem with tobacco smoking is its enormous implications on health. According to Centers for Disease Control and Prevention it was estimated that in 2009 smoking related diseases world- wide cause some 5 million deaths per year and that the current trends show that tobacco use will cause more than 8 million deaths annually by 2030. In the United States tobacco use is responsible for one in about five deaths, which 25 means about 450 000 deaths per year. In many large and less developed countries the incidence of tobacco related deaths is even higher In the United States cigarette smoking costs about 100 billion USD in lost productivity and about 100 billion USD in WO 2013/103318 PCT/SE2013/050005 2 health care expenditures, In fact, excessive smoking is now recognised as one of the major health problems throughout the world. This grim consequence of tobacco smoking has urged many medical associations and health authorities to take very strong actions against the use 5 of tobacco. Even though tobacco smoking is decreasing in many developed countries today it is hard to see how the societies could get rid of the world's second most used drug. The incidence of smoking is still rising in many countries, especially in less developed countries, 10 The most advantageous thing a heavy smoker can do is to stop smoking completely or at least to reduce his/her smoking. Experience shows, however, that most smokers find this extremely difficult since, mostly, tobacco smoking results in a dependence disorder or craving. The World Health Organization ("WHO") has in its International Classification of Disorders a diagnosis called Tobacco Dependence. is Others like the American Psychiatric Association call the addiction Nicotine Dependence, It is generally accepted that these difficulties to stop smoking result from the fact that those heavy smokers are dependent on nicotine. The most important risk factors related to health are, however, substances that are formed during the combustion of tobacco, such as carcinogenic tar products, carbon monoxide, N-nitrosamines, aldehydes, and 20 hydrocyanic acid. Effects of nicotine Nicotine is an addictive alkaloid, C 5
    H
    4
    NC
    4
    H-NCH
    3 , derived from the tobacco plant. Nicotine is also used as an insecticide. The administration of nicotine (for example, in the form of smoking a cigarette, cigar or pipe) can give a pleasurable feeling to the 25 smoker. However, smoking has health hazards and it is, therefore, desirable to formulate an alternative way of administering nicotine in a pleasurable and harmless manner that can be used to facilitate withdrawal from smoking and/or used as a replacement for smoking.
    WO 2013/103318 PCT/SE2013/050005 3 When smoking a cigarette, nicotine is quickly absorbed into the smoker's blood and reaches the brain within around ten seconds after inhalation, The quick uptake of nicotine gives the consumer a rapid satisfaction, or kick. The satisfaction usually lasts during the smoking time of the cigarette and for a period of time thereafter. The 5 poisonous, toxic, carcinogenic, and addictive nature of smoking has provided strong motivation to develop methods, compositions and devices, which can be used to break the habit of smoking cigarettes. Nicotine replacement products One way to reduce smoking is to provide nicotine in a form or manner other than 10 by smoking and some products have been developed to fulfil this need. Nicotine containing formulations are currently the dominating treatments for tobacco dependence, The successes in achieving reduction in the incidence of smoking have been rela tively poor using presently known products. The present state of the art involves both behavioural approaches and pharmacological approaches. More than 80 % of the 1s tobacco smokers who initially quit smoking after using some behavioural or pharmacological approach to singly reduce smoking incidence generally relapse and return to the habit of smoking at their former rate of smoking within about a one year's period of time. As an aid for those who are willing to stop smoking there are several ways and 20 forms of nicotine replacement products available on the market Several methods and means have been described for diminishing the desire of a subJect to use tobacco, which comprises the step of administering to the subject nicotine or a derivative thereof as described in e g U.S. Patent Number 5,810,018 (oral nicotine-containing spray), U.S. Patent Number 5,939,100 (nicotine- containing micro spheres) and U.S. Patent Number 25 4,967,773 (nicotine-containing lozenge). Nicotine-containing nose drops have been reported (Russell et al., British Medical Journal, Vol. 286, p. 683 (1983); Jarvis et al.. Brit. J. of Addiction, Vol. 82, p. 983 (1987)). Nose drops, however, are difficult to administer and are not convenient for use at work or in other public situations. Administrating nicotine by way of delivering directly into the WO 2013/103318 PCT/SE2013/050005 4 nasal cavity by spraying is known from U.S, Patent Number 4,579,858, DE 32 41 437 and W093/12764. There may be local nasal irritation, however, with use of nasal nicotine formulations. The difficulty in administration also results in unpredictability of the dose of nicotine administered. 5 The use of skin patches for transdermal administration of nicotine has been reported (Rose, in Pharmacologic Treatment of Tobacco Dependence, (1986) pp. 158 166, Harvard Univ. Press). Nicotine-containing skin patches that are in wide use today can cause local irritation and the absorption of nicotine is slow and affected by cutaneous blood flow. i0 Also, inhaling devices resembling a cigarette are known for uptake of nicotine va pours as suggested in U.S. Patent Number 5,167,242. Said means and methods address the problems associated with addiction to nicotine. One successful product that is used as a smoking substitute and/or as a smoking cessation aid and which is based on nicotine is the chewing gum Nicorette*. This 15 product was one of the first nicotine replacement forms that was approved by the Food and Drug Administration (FDA) and is still one of the most used nicotine replacement products. Nicorette® chewing gum has been on the market in about 60 countries for several years. In this chewing gum the nicotine is present in the form of a complex with an insoluble cation-exchanger (polacrilex) that is dispersed in a gum base. The nicotine 20 is slowly released from the gum due to chewing and will reach similar plasma levels as when smoking a cigarette after about 30 minutes depending on the chewing technique, i e slow or active. Patents related to this product are e g U.S. Patent Number 3,877,468, U.S. Patent Number 3,901,248 and U.S. Patent Number 3,845,217. 25 Pharmaceuticals intended for oral administration are typically provided in solid form as tablets, capsules, pills, lozenges, or granules. Rapidly dissolving tablets are often employed in the administration of pharmaceuticals where it is impractical to provide a tablet for swallowing whole, for instance with paediatric patients. Several WO 2013/103318 PCT/SE2013/050005 5 workers in the field have explored rapidly disintegrative tablets, e g U.S. Patent Nos; 6,106,861 and 6,024,981 and PCT Application No. WO 99/47126. Pharmaceutical tablets for intraoral delivery of nicotine presently available on the market include Commit® Lozenge or NiQuitin Olozenge, a nicotine-containing tablet 5 manufactured by GlaxoSmithKline, and Nicorette Microtab@ Sublingual Tablet, a nicotine-containing tablet manufactured by McNeil AB. Many subjects using said tablets experience organoleptically disturbing sensations induced by the nicotine and/or by excipients. Hence, although release of nicotine in the oral cavity and/or within the pharynx 10 from solid pharmaceutical dosage forms is a convenient means for administration of nicotine sufficient reduction of organoleptically disturbing sensations induced by the nicotine and/or by non-active excipients of the dosage forms remains an unsolved problem. Prior art and problems thereof 15 Ingredients in the above-mentioned pharmaceutical tablets for intraoral delivery of nicotine, which seemingly could have an effect on reducing organoleptically disturbing sensations, comprise one or more flavoring agents and one or more sweeteners. Hence said one or more flavoring agents and said one or more sweeteners do not sufficiently contribute to reducing the organoleptically disturbing sensations related to intraoral 20 delivery from the tablet. One possible reason to why the one or more flavoring agents and the one or more sweeteners do not sufficiently contribute in reducing said organoleptically disturbing sensations may be that the nicotine has to be dissolved in the saliva in order to be absorbed. Once the nicotine is dissolved in saliva the organoleptically disturbing sensations induced by the nicotine cannot be reduced. The 25 same applies for excipients inducing organoleptically disturbing sensations. The article "Taste Masking of Ondansetron Hydrochloride by Polymer Carrier System and Formulation of Rapid-Disintegrating Tablets, by Shagufta Khan, Prashant Kataria, Premchand Nakhat, and Pramod Yeole, published June 22, 2007 in WO 2013/103318 PCT/SE2013/050005 6 AAPS PharmSciTech, discloses taste-masking of the bitter taste of the antiemetic drug ondansetron HCL and subsequent formulation of a rapid-disintegrating tablet (RDT) of the taste-masked drug. Such taste-masking, often called microencapsulation, is though unsatisfactory in the present context. This is because the granules are not intended to 5 release the API in the oral cavity upon being disintegrated from the tablet in the mouth. Hence, coating of individual particles or granules according to the above article does not solve the present problem. In order to be effective NRT product nicotine has to be absorbed primarily by the oral mucosa if orally administered The tobacco industry knows that menthol overrides the harsh taste of tobacco 10 during smoking and alleviates nicotine's irritating effects, synergistically interacts with nicotine, stimulates the trigeminal nerve to elicit a 'liking' response for a tobacco product, and makes low tar, low nicotine tobacco products more acceptable to smokers than corresponding non-mentholated tobacco products. See Menthol's potential effects on nicotine dependence: a tobacco industry perspective", Valerie B Yerger, Tobacco 15 Control 2011; 20(Suppl 2):ii29eii36. doi:10.1136/tc.2010.041970. This publication though does not disclose any use of menthol for reducing one or more organoleptically disturbing sensations in solid pharmaceutical dosage forms that are characterized in that it is provided with at least one film coating for reduction for release of nicotine in the oral cavity. Furthermore, the current invention is related to the surprising effect of the 20 combination of film coating, flavor and/or sweetener in a solid pharmaceutical dosage form for release of nicotine in the oral cavity and is not restricted to the use of menthol. Hence, there is a need for a convenient and more efficient way to further reduce said organoleptically disturbing sensations. In particular, there is a need for nicotine replacement therapies suitable for use in humans having improved tolerability when 25 administered orally. EP1430896 (KYUKYU YAKUHIN KOGYO KK) discloses a multi-laminate film where a nicotine-containing layer is laminated against two coating layers. It is not though disclosed that this formulation comprises any component for reduction of an organoleptically disturbing sensation.
    WO 2013/103318 PCT/SE2013/050005 7 W003003957 (LAVIPHARMA LAB INC) discloses a quick dissolving oral mucosal drug delivery device, comprising a mucosal drug-containing surface-coat forming inner layer disposed between two moisture barrier coating layers, It is not disclosed that the two moisture barrier coating layers are devoid of the drug. s W02004056363 (NICONOVUM AB ET AL) discloses a nicotine-containing particulate material, which may be coated with a film-forming polymer. It is not disclosed that this polymer may be devoid of nicotine, EP1666030 (PFIZER HEALTH AB) discloses nicotine-containing lozenges. It is not disclosed that these lozenges may be provided with a film coating comprising a film 10 forming polymer, further said film coating being devoid of nicotine and devoid of buffer. Definitions The below definitions apply mutatis mutandis on expressions being similar to those being defined below. The term "Active Pharmaceutical Ingredient (API)", also called Drug Substance, is is herein intended to mean a substance or mixture of substances intended to be used in the manufacture of a drug (medicinal) product and that, when used in the production of a drug, becomes an active ingredient of the drug product. Such substances are intended to provide pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment, or prevention of disease or to affect the structure and function of the body. 20 The term "intraoral" is herein intended to mean within the oral cavity. The term "release" as a verb is herein intended to mean to liberate an API, here nicotine, from its dosage form and to make the API available in dissolved form for subsequent absorption. The term "release" as a noun is to be understood correspondingly. 25 The term "organoleptically disturbing sensation" is herein intended to mean a sensation perceived as negative in the oral cavity. Non-limiting examples of such sensations are irritation, acridity, taste alteration and taste blocking, feelings of burning, WO 2013/103318 PCT/SE2013/050005 8 astringing, bitterness and tingling, off tastes such as sour, salty, metallic, soapy, musty, sulphurous, pungent, fatty and foul tastes, Said organoleptically disturbing sensations may be induced by an API, here nicotine, or by non-active excipients Non-limiting examples of such sensations specifically induced by nicotine are irritation, acridity, 5 feelings of burning, bitterness and tingling, off tastes such as sour, salty, metallic, soapy, fatty and foul tastes. The present application encompasses organoleptically disturbing sensations regardless of their perceived intensity. The term "organoleptically disturbing substance" is herein intended to mean a substance that may induce an organoleptically disturbing sensation. Organoleptically 10 disturbing substances may encompass APIs, here nicotine, and non-active excipients. Whether a substance induces an organoleptically disturbing sensation or not may be established by methods known in the art, such as commonly used methods for characterizing organoleptic parameters of food and beverages, such as wine. Non limiting examples of such methods are e g found in "Sensory Evaluation A practical 1s Handbook", Sarah E. Kemp, Tracey Hollowood and Joanne Hort, Wiley-Blackwell 2011, "Sensory Evaluation Techniques, Fourth Edition, Morten C. Meilgaard, Gail Vance Civille and B. Thomas Carr, CRC Press 2007, and "Sensory Evaluation of Food, Principles and Practices, Second Edition", Harry T. Lawless and Hildegarde Heymann, Springer 2010. 20 The term "off taste" is herein intended to mean an unpleasant taste or an unpleasant after taste. The term "encapsulate" is herein intended to mean cover entirely or partly. The term "core" is herein intended to mean an uncoated solid pharmaceutical dosage form. In other words a core is what you place a coating on to get a coated solid 25 pharmaceutical dosage form. One may also say that a core is encapsulated with a coating to get a coated solid pharmaceutical dosage form.
    WO 2013/103318 PCT/SE2013/050005 9 Smar oftheinvention The present invention seeks to address the problem of needing to reduce one or more organoleptically disturbing sensations induced by one or more organoleptically disturbing substances being released in the oral cavity from a solid nicotine-comprising 5 pharmaceutical dosage form. Thus, the invention provides a solid pharmaceutical dosage form for the release of nicotine in the oral cavity comprising a core encapsulated by at least one film coating, wherein the core comprises nicotine and wherein the film coating comprises at least one film-forming polymer and at least one component for reduction of one or more 1o organoleptically disturbing sensations. Optionally the dosage form may comprise a further API, e g zinc acetate and other salts or complexes with zinc. Said reduction in organoleptically disturbing sensations should preferably not noticeably deteriorate the pharmaceutical effect of the nicotine or the API. 15 The invention further provides therapy systems comprising a therapy system of the invention together with one or more further nicotine replacement therapies (such as transdermal patches, gums, mouth sprays, and the like). The dosage forms and therapy systems of the invention may be used in human medicine in the treatment of a disease selected from the group consisting of tobacco or 20 nicotine dependence, Alzheimer's disease, Crohn's disease, Parkinson's disease, Tourette's syndrome, ulcerous colitis and post-smoking-cessation weight gain. Detailed description of the invention The present solid pharmaceutical dosage form mainly erodes in the mouth whereby nicotine is released and exposed to intraoral sensory receptors, e g taste 25 receptors and trigeminal receptors. Preferably the nicotine is essentially absorbed by the mucosa of the oral cavity. Non-limiting examples of said pharmaceutical dosage form are tablet dosage forms intended to be completely dissolved in the oral cavity, such as WO 2013/103318 PCT/SE2013/050005 10 lozenges, sublingual tablets, buccal tablets and orally disintegrating tablets. Said solid pharmaceutical dosage form is not intended to be swallowed. The nicotine is preferably for treating tobacco dependence The nicotine may be in any pharmaceutically-acceptable form, such as a nicotine 5 salt, the free base form of nicotine, a nicotine derivative, such as a nicotine cation exchanger, a nicotine inclusion complex or nicotine in any non-covalent binding, nicotine bound to zeolites, nicotine bound to cellulose including micro-crystalline cellulose, or starch micro-spheres and/or mixtures thereof. The present problem is also of specific interest for certain excipients, non-limiting 10 examples of which are buffers, such as carbonate (including bicarbonate or sesquicarbonate), glycinate, different phosphate systems such as trisodium phosphate, disodium hydrogen phosphate; and tripotassium phosphate, dipotassium hydrogen phosphate, glycerophosphate or citrate of an alkali metal (such as potassium or sodium, or ammonium), e g trisodium and tripotassium citrate, different hydroxides, amino acids, 15 and mixtures thereof, and other excipients that may induce organoleptically disturbing sensations. When you administer an API, such as nicotine, with a solid pharmaceutical dosage form the API is continuously released as long as the dosage form remains in the mouth. If you do not suck or otherwise mechanically process the dosage form, less API, 20 and less excipients, is released compared to if you suck and/or otherwise mechanically process it. By stopping to suck and/or otherwise mechanically process the dosage form said organoleptically disturbing sensations are normally still not sufficiently reduced. One way to sufficiently reduce said organoleptically disturbing sensations for a lozenge or a sublingual tablet could be to remove the dosage form from the mouth and 25 put it back into the mouth once the organoleptically disturbing sensations have sufficiently waned. This is though a very inconvenient way to reduce said organoleptically disturbing sensations. For fast dissolving tablets and rapidly WO 2013/103318 PCT/SE2013/050005 11 disintegrating tablets this option is not available as these tablets would fall apart if they should be taken out from the mouth, The intention with the present invention is though to keep the dosage form in the oral cavity until substantially dissolved or disintegrated and still reduce organoleptically 5 disturbing sensations. If the dosage form instead would be temporarily removed from the mouth as described above this would be not only very inconvenient, but the release of the API would be temporarily stopped, which normally is unwanted inter alia because that may affect the intended dosage regime. Pharmaceutical tablets for intraoral delivery of nicotine presently available on the 10 market include Commit@,) Lozenge or NiQuitinR lozenge, a nicotine-containing tablet manufactured by GlaxoSmithKline, and Nicorette Microtab@ Sublingual Tablet, a nicotine-containing tablet manufactured by McNeil AB. Many subjects using said tablets experience organoleptically disturbing sensations induced by the nicotine and/or by excipients. 15 Ingredients in said tablets, which seemingly could have an effect on reducing organoleptically disturbing sensations, comprise one or more flavoring agents and one or more sweeteners. Hence said one or more flavoring agents and said one or more sweeteners do not sufficiently contribute to reducing the organoleptically disturbing sensations related to intraoral delivery from the tablet. One reason to why the one or 20 more flavoring agents and the one or more sweeteners do not sufficiently contribute in reducing said organoleptically disturbing sensations may be that nicotine has to be dissolved in the saliva in order to be absorbed. Once the nicotine is dissolved in the oral cavity the organoleptically disturbing sensations induced by the nicotine cannot be reduced. The same applies for excipients inducing organoleptically disturbing sensations. 25 ~The present invention provides a solution to the above-mentioned problem of reducing one or more organoleptically disturbing sensations induced by one or more organoleptically disturbing substances being released in the oral cavity and/or within the pharynx from a solid nicotine-comprising pharmaceutical dosage form. The solution resides in providing said solid dosage form with at least one film coating for reduction of WO 2013/103318 PCT/SE2013/050005 12 one or more organoleptically disturbing sensations comprising at least one film-forming polymer and at least one component for reduction of one or more organoleptically disturbing sensations, which in combination reduce at least one of said organoleptically disturbing sensations, 5 Said at least one component for reduction of one or more organoleptically disturbing sensations may by way of example, but not exclusively, be one or more flavoring agents and/or one or more sweeteners. Preferably said at least one film coating is devoid of nicotine and devoid of any other API and/or devoid of any buffer. 10 Said reduction of organoleptically disturbing sensations preferably does not significantly affect the release of the nicotine, The core of the present solid dosage form preferably has a weight from 50 mg to 2000 mg, more preferably from 90 mg to 1200 mg. The film coating on the core preferably has a weight of from 1 % to 15 % of the weight of the core. Is The thickness of the film coating has an influence on the degree of reduction of the organoleptically disturbing sensations. Preferably the film coating has an average thickness from 10 to 500 microns, more preferably from 20 to 250 microns, and most preferably from 30 to 150 microns. The actual film thickness is adapted in dependence of different parameters, such as the organoleptic sensation to be reduced, the 20 concentration of flavour, the type of flavour sweetness compounds used and their relative levels and amounts used. The film thickness may be measured using different methods known in the art such as SEM (Scanning Electron Microscopy), digital micrometer, X-ray microtomography, terahertz pulsed imaging etc. See further e g Quantitative Analysis of Film Coating in a Pan Coater Based on In-Line Sensor 25 Measurements, Jose D. Perez-Ramos et al, AAPS PharmSciTech 2005; 6 (1) Article 20, Nondestructive analysis of tablet coating thicknesses using terahertz pulsed imaging, J Pharm Sci. 2005; 94:177Y183. Fitzgerald AJ, Cole BE, Taday PF., Hancock B, WO 2013/103318 PCT/SE2013/050005 13 Mullarney MP. X-ray microtomography of solid dosage forms. Pharm Technol. 2005:29:92Y100. A rapid dissolution or disintegration of the at least one film coating is instrumental for not impairing the release of the nicotine. Hence, it is of importance that to an 5 essential degree the at least one film coating dissolves or disintegrates rapidly, preferably in less than 2 minutes, more preferably in less than 1 minute and most preferably in less than 30 seconds, from the moment of administration Too long a time for release of the nicotine may impair the user friendliness. Hence, the solid dosage form may preferably release the nicotine within 30 minutes, 10 more preferably within 15 minutes, from the moment of administration. The film-forming polymers may in a non-limiting way be chosen among cellulose ethers e g hydroxy propyl methyl cellulose (HPMC), methyl hydroxy ethyl cellulose (MHEC), hydroxy propyl cellulose (HPC), hydroxyethyl cellulose (HEC), ethyl hydroxyl ethyl cellulose (EHEC), and other film forming polymers such as methacrylic acid 15 copolymer-type C sodium carboxy methyl cellulose, polydextrose, polyethylene glycols, acrylate polymers (e g poly vinyl acrylate (PVA)),polyvinyl alcohol-polyethylene glycol graft copolymers, complex of polyvinylpyrrolidone (PVP), such as povidone, polyvinyl alcohol, microcrystalline cellulose, carrageenan, pregelatinized starch, polyethylene glycol, and combinations thereof. Typically, the molecular weight (weight average 20 and/or number average) of the polymer is from 1,000 to 10,000,000, preferably from 10,000 to 1,000,000, as measured by gel permeation chromatography. Optionally, a plasticizer may be added to the film-forming polymer to facilitate the spreading and film forming capability. Examples on useful plasticizers are glycerol, propylene glycol, polyethylene glycol (PEG 200-6000), organic esters e g triacetin 25 (glyceryl triacetate), triethyl citrate, diethyl phtalate, dibutyl phtalate, dibutyl sebacete, acetyltriethyl citrate, acethyltributyl citrate, tributyl citrate, and oils/glycerides such as fractionated coconut oil, castor oil and distilled acetylated monoglycerides. Additionally, or alternatively, surfactants may be included to facilitate the incorporation of flavors and to improve penetration and spreading properties of the coating liquid. Non-limiting WO 2013/103318 PCT/SE2013/050005 14 examples of surfactant are polysorbates derived from PEG-ylated sorbitan esterified with fatty acids such as Polysorbate 20 (Polyoxyethylene (20) sorbitan monolaurate), Polysorbate 40 (Polyoxyethylene (20) sorbitan monopalmitate), Polysorbate 60 (Polyoxyethylene (20) sorbitan monostearate), Polysorbate 80 (Polyoxyethylene (20) 5 sorbitan monooleate) (e g Tween 80, Tween 40, Tween 20), sodium lauryl sulphate (SLS), poloxamer surfactants i.e. surfactants based on ethylene oxide - propylene oxide block copolymers and other surfactants with high HLB-value, Anti-tacking agents/glidants may in a non-limiting way be chosen among compounds such as talc, magnesium stearate, kaolin, colloidal silicon dioxide and 10 glyceryl monostearate, The aforementioned agents may also be included to reduce sticking issues. The flavoring agents may in a non-limiting way be chosen among natural or synthetic flavouring or aromatizing agents and may be added as liquids and/or as powder. Flavour and aroma agents may be selected from essential oils including 15 distillations, solvent extractions, or cold expressions of chopped flowers, leaves, peel or pulped whole fruit comprising mixtures of alcohols, esters, aldehydes and lactones; essences including either diluted solutions of essential oils, or mixtures of synthetic chemicals blended to match the natural flavour of the fruit, (e g strawberry, raspberry, black currant, banana, melon, cherry, passion fruit, pineapple, peach, blackberry, mango, 20 papaya, guava, cranberry, cloudberry, violet, pomegranate, pear, apple); artificial and natural flavours of brews and liquors, (e g cognac, whisky, rum, gin, sherry, port, and wine); tobacco, coffee, tea, cocoa, and mint; fruit juices including expelled juice from washed, scrubbed fruits such as lemon, orange, lime and other citric fruits; spear mint, pepper mint, lemon balm. wintergreen, cinnamon, cacoe/cocoa, vanilla, liquorice, 25 menthol, eucalyptus, aniseeds, nuts (e g peanuts, coconuts, hazelnuts, chestnuts, walnuts, colanuts), almonds, raisins and ginger; and powder and flour. The sweeteners may in a non-limiting way be chosen among synthetic or natural sugars, i e any form of carbohydrates suitable for use as sweetener, as well as so called artificial sweeteners such as saccharin, sodium saccharin, aspartame, e g NutraSweet@, WO 2013/103318 PCT/SE2013/050005 15 acesulfarne or Acesulfame K@, potassium acesulfame, thaumatin, glycyrrhizin, sucralose, dihydrochalcone, miraculin, monellin, stevside, e g Stevia®., neotame, N substituted APM derivatives, cyclamic acid and its salts and alitame. Sweeteners may also be selected from the group consisting of sugar alcohols, such as sorbitol, xylitol, 5 single sugars including sugars extracted from sugar cane and sugar beet (sucrose), dextrose (also called glucose), fructose (also called leavulose), and lactose (also called milk sugar); sorbitol, mannitol, glycerol, xylitol, erythritol, maltitol syrup (or hydrogenated starch hydrolyzate), isomalt, lactitol; and mixtures of sugars including glucose syrup, (e g starch hydrolysates, containing a mixture of dextrose, maltose and a range of complex in sugars), invert sugar syrup, (e g sucrose inverted by invertase (also called sucrase or sacchrase) containing a mixture of dextrose and fructose), high sugar content syrups such as treacle and honey containing a mixture of particular leavulose, dextrose, maltose, lactitole, sucrose, resins, dextrin and higher sugars; and malt or malt extracts. Other adjuvants may also be included in the composition of the film such as is coloring agents, opacifiers, glossing agents, pore forming agents, excipient stabilizers. The dosage forms of the invention may be prepared by way of a variety of routine techniques, and using standard equipment, known to the skilled person (see, for example, Lachman et al, "The Theory and Practice of Industrial Pharmacy", Lea & Febiger, 3r edition (1986) and "Remington: The Science and Practice of Pharmacy" 20 Gennaro (ed.), Philadelphia College of Pharmacy & Sciences, 19* edition (1995)). In one embodiment, a core comprising nicotine is first produced using known tabletting techniques, which is then coated with a solution containing a film-forming polymer. Standard mixing equipment may be used for mixing together components of compositions of the invention. The mixing time period is likely to vary according to the 25 equipment used, and the skilled person will have no difficulty in determining by routine experimentation a suitable mixing time for a given combination of ingredient(s). Surprisingly, after that the film coating essentially has disappeared from the surface of the solid dosage form the reduction of organoleptically disturbing sensations remains.
    WO 2013/103318 PCT/SE2013/050005 16 Equally surprisingly, when incorporating said components for reducing organoleptically disturbing sensations in the core of the solid dosage form, instead of incorporating those in the film coating said organoleptically disturbing sensations will not be sufficiently reduced. 5 Upon it having been dissolved a film coating on its own has a limited effect on the reduction of organoleptically disturbing sensations. A component for reduction of said sensations, such as a flavoring agent or a sweetener, may have a limited effect on its own on the reduction of organoleptically disturbing sensations. Surprisingly the combined effect of a film coating and at least one further component for reduction of 10 said sensations, provides an effect that is more profound than the sum of the effects of the film coating on its own and the at least one further component on its own. Reducing organoleptically disturbing sensations implies increased therapy adherence, which may lead to increased efficacy of the treatment. Examples 15 The below examples on embodiments and manufacturing of the present formulation as well as on testing the present formulations are non-limiting and for illustrating the present invention. Alternatives and variations of the below examples within the scope of the present invention as per the below claims may be carried out by a person skilled in the art, Ingredients as per the below examples may be exchanged for 20 equivalent ingredients. The combination of tablet cores and film coatings in the examples given are arbitrary. Any film coating can be combined with any tablet core. Example I Manufacturing method The composition for a batch of tablet cores is given below in Table Al. The 25 materials are sieved using an oscillating sieve with 1mm mesh size and thereafter blended, according to methods known in the art e g using a double cone blender for 10 to 30 minutes. The blended materials are then compressed into tablets by means of WO 2013/103318 PCT/SE2013/050005 17 direct compression. The powder compression may for example be performed using a rotary tablet press with 15 mm round concave punches. The tablets are compressed to sufficient hardness to enable an acceptable coating process and to achieve the desired in vivo dissolution time. 5 Table IA: Components of the tablet core, e sjPercent mg/portion (w/w) [Nicotine ret~ complex 2%ncte)15 -15* S r bi t ol 8__ _ I 9D__ 890 ------ Sodium bicarbonate 0 2.5 Sodium carbonate --- 05 5 Mint flavor 0 Manesiurm ea rate 1.5 15 * Equivalent to 3 0 rng dose of nicotine base Table I B provides numerous alternative non-limiting examples of tablet core compositions. Table 1 B: Components of the tablet core. Ingredients Percent (wiw) mg/portion Nicotine resin complex (20% nicotine)* 0.2 2 60 Sorbito --- 9-- - - - --..- - - 9 0 -9915 0-991 5 Mannitol (- 99 15 0-991 5 Sodium p bicroae_ _ 010{0 - 15 Sodiumn carbonate 0-1. 01 Flavor (mint and/or rut and/or other) 0.05 - 2 5 0 5 - 25 Magnesium start 0. 5255 Steam 5-2.5 TOTAL 1 00 0 1000.0 10 * or other source equivalent to 0.5 mg to 12 mg nicotine base. ** or other high intensity sweetener or combination of such sweeteners.
    WO 2013/103318 PCT/SE2013/050005 18 Film coating of the tablets can be performed using e g a standard modern pan coater equipped inter alia with air atomized spray nozzles to distribute the film coating fluid and a perforated drum of appropriate size. The film solution is prepared by adding the hydroxypropyl methylcellulose and plasticizer (if such is included in the composition) 5 to purified water (>85'C) whilst stirring. The most suitable temperature of the solvent used for dispersing the hydroxypropyl methylcellulose depends on the type of hydroxypropyl methylcellulose used. There is abundant information in the literature regarding hydroxypropyl methylcellulose film preparation e g from polymer manufacturers such as Dow Inc. 10 http://dowwolff.custhelp.com/app/answers/detail/aid/I 094/kw/prepare/session/L3RpbW UvMTMyMzY3MzM3Ny9zaWQvMkFoOUVuTGs%3D and http://dowwolff.custhelp.com/app!answers/detail/ajid/1 181. The film solution is cooled to approximately 20CC and sucralose is added when the solution is approximately 400C. The solution is allowed to settle at ambient conditions for at least 3 hours where after the 15 solution is homogenized using a Silverson homogenisator. Thereafter flavor mixture is added containing Polyoxyethylene (80) sorbitan monooleate and mint flavor. The resulting mixture is stirred until it is homogenous. The components of the film coating composition are given below and in other examples are provided as the calculated amount per unit dosage form. The sum of the "dry excipients", also referred to as "solids 20 content" is usually in the range 5-25 % w/v of the total coating solution. The actual solids content chosen depends on the composition and coating process parameters. Table 1C: Components of the film coating, Ingredients lPercent (w/w) mg/port:on H %droxvgrovi me c iose 79.7 19925 ethylene (20) sorbitan monooe3 ont flavor (or i Fruit flavor) cominti 12o0 s Sum "' Fxcipienlts ___ 0. 2 Ac-ua pur a.q or other high intensity sweetener or combination of such sweeteners, WO 2013/103318 PCT/SE2013/050005 19 ** Aqua. Pur. is added q.s. to achieve a dry content suitable for the coating process parameter setting to be applied e.g. dry content in the range 10% w/w to 25% w/w. A coloring component may also be included, e g titanium dioxide. Table 1D: Components of an alternative film coating Ingredients Percent (w/w) mg/portion Hvd roxypropyl methylcel Iulose_______I80.45 __ _32.28 Polvethyleneglycol 400* 8,2 3.28 Poly oxyethyiene (20) sorbitan monooeate 0 1 0.04 Titanium dioxide 6 2.4 Aspartame __-40 1 Fruit flavor (orq a Mint flavor) 25 05 Sum "Dry" Excipients __-100.0 40 Aqua pur* _ _ _ __ _ _ _ gs. * Aqua. Pur. is added q.s. to achieve a dry content suitable for the coating process parameter setting to be applied. Table 1E: Components of additionally non-limiting alternative film coatings ngred ents Percent (w/w) r g/portion Hroxypropy hyleuose 44,5-970 8.9-19.4 Po letheqcol 400 0.___ 5 0 o ye'thEn:o 0 1 Pvoxvethv ,len.e (20)--- sorbitanmmmmmmmmmmmmmmmm.0.. ... 0-0 . Titaniumd oxide optional irein S ucralose 4 1___ fruit flavor (orqe g a Mint flavor) 0 2 5-10 0.5 2 Sum "Dry'" Excipients 010 0 A qu -u- q- ---------...-. TFhe hydroxypropyl methylcellulose may e gtbe of type miethocel E3, K4, E5 or FVLV., The hydroxypropyl methylcellulose may also be replaced in part or in its entire by a 10 combination of other film forming polymers. 2 May be exchanged for propylene glycol, glycerol triacetin or other plasticizer, 3 May be exchanged for other surfactant. 4 Alternatively sodium lauryl sulphate or equivalent surfactant, WO 2013/103318 PCT/SE2013/050005 20 5 Alternatively other high intensity sweetener or combination of such sweeteners. Sweetener may also be included in the flavor. 6 Aqua. Pur. is added q.s. to achieve a dry content suitable for the coating process parameter setting to be applied and is essentially evaporated during the process. Manufacturing method of tablets as per Example 1 Table 2A: Components of the tablet core, redients r(ww) mg/portion Nicotine resin cornpex 2 nicotine) 1,67 I soma-t -- 93.56 561 36 Sodium carbonate1 1 0 Mint flavor -1 _7 Coolinq agent 0.1 0.6 Macnesiun stearate ------ .2 12 0 Silicon dioxide_(colloidal ___~0.5 3.0 --- ------ -- -- O- --- --- - - ... .. TOTAL 60 1o * Equivalent to 2.0 mg dose of nicotine base. If nicotine resin complex with other degree of nicotine loading is used, e g 15%, then the amount of polyol is adjusted accordingly. Film coating of the tablets produced in 2A can be performed using e g a standard modern pan coater equipped with air atomized spray nozzles to distribute the film coating fluid and a perforated drum of appropriate size. The film solution is prepared by 15 adding the hydroxypropyl methylcellulose to aqua purificata during stirring and then the solution is allowed to settle overnight at ambient conditions where after polyvinyl alcohol, polyethylene glycol 400 and sucralose are added during stirring. The solution is homogenized using a Silverson homogenisator. Thereafter flavor mixture containing Polyoxyethylene (80) sorbitan monooleate and mint flavor is added. The resulting 20 mixture is stirred until it is homogenous.
    WO 2013/103318 PCT/SE2013/050005 21 Table 2B: Components of the film coating. IngredientsPeenw/)mpotn ...... _ _ _ ........... ..... --- .. ... .. Hydroxypropyl methlceilulose 56 5 14.13 Polyvinyl alcohol 12 3.0 Poythlnglcl400* 164 Polyoxyethylene 80) sorbitan monooleate 0 3 0.08 Sucralos ___2 ~ 1.8
    SSSSSSSSSSSSSSSSSSSSSSSSS----
    Mint flavor _ 8 2 Sum 'Dry" Expients** 100 25 Aqua-pur* ___--- . .... ..... * Or other plasticizer e g triacetin, i.e. 1,2,3-triacetoxypropane, glycerol or propylenglycol, which usually are used at concentration of 10-35% based on polymer weight. ** Sum excipients other than Aqua pur. 5 ***Aqua. Pur. is added q.s. to achieve a dry content suitable for the coating process parameter setting to be applied e g may the dry content be 16% w/w. Example 3 As per Example 2 with a total weight of the tablet core of 650 mg using oval 14.5 mm punches, but without sodium hydrogen carbonate and/or sodium carbonate (which 10 is compensated by amount of Mannitol). Additionally the components of the film coating are provided in Table 3A. Table 2B: Components of the film coating, n-nPercent(ww) mg/port on PzDry"ns* t 0s . ... .............---------.-.-......... .--------- ........ Hvdroxvpro-nvl, methlcellulose '56.5 14. 13" Sucra--ose ......----......... i Povthlneivcl400 16r 3 '4. 0 8 ------........................... ........ Sum "Dy xiins__ 00 ~ 25,0 ---- Aqua pur S' Sum excipients other than Aqua pur, WO 2013/103318 PCT/SE2013/050005 22 **Aqua. Pur. is added q.s. to achieve a dry content suitable for the coating process parameter setting to be applied e g may the dry content be 16% w/w. Exaple 4 Manufacturing method as per Example 1, 5 Table 4A: Components of the tablet core, Ingredients JPercent (w/w) mg/portion Nicotine re sn complex 20% nicoi ne) --- 0 mann______ 935---------- ......... ----- Sodium hydrogen carbonate 0 5 4 0 Sodium 4,0 jf,'ruit flavor _ 180 Maqnesi-----m start ..... 200.__ * Equivalent to 4.0 mg dose of nicotine base. If equivalent amount of nicotine base is supplied by means of nicotine resin complex with other degree of nicotine loading is used e g 15% or nicotine bitartrate then the amount of polyol is adjusted accordingly. Film coating of the tablets can be performed using e g a standard modern pan 10 coater equipped inter alia with air atomized spray nozzles to distribute the film coating fluid and a perforated drum of appropriate size. Table 48: Components of the film coating. ng-edients Percent( w/w) mg/portion Hdoyrplmethycelulo0se 12 6,2 aceti 2,to7 625 Polyxyethylene (80) sorbitan monooleate 0,1 0.035 Suros ___ 74 25 A* nflavor5 Mintfffffffffffffffffffffffffffff... - --------- ------ Sum "Dry" Epjents 00 35 May be exchanged for another plasticizer, such as polyethyleneglycol 1000, WO 2013/103318 PCT/SE2013/050005 23 **Aqua. Pur. is added q.s. to achieve a dry content suitable for the coating process parameter setting to be applied. The concentration of hydroxypropyl methylcellulose may for example be 7% w/w. Example 5. 5 Manufacturing method as per Example 1 Table 5A: Components of the tablet core, ngredien ts Percent w/w) mgiport ion NicotneWcodxinnt ___ 8 , 55 .5 dcycldex in -6-- - -8 iospovidonel hoo ------------- --- v ------- ion) Sodium cbonae a drous 55 Mint flavor 5 Magpesium stearat 0.. Colloidalsilicon dioxide TOTL 10 * Equivalent to 1.0 mg dose of nicotine base. Film coating of the tablets can be performed using e g a standard modern pan coater equipped inter alia with air atomized spray nozzles to distribute the film coating 1o fluid and a perforated drum of appropriate size. Table 5B: Components of the film coating, ingredients Percent (w/w) m ron * ydoxprpymethygcely9q>s7 Povxyethylene (80) sorbitan nonooleate S urase4,9 049 Acesulfane potassium (Potasm 6-me 0.4 --- --- --- --- --- v-----------------
    --
    Aspartame (. .(.Asparty)pheny.ane) 2 0.2 Mit flavor 151 Sum "Dry" Exipients 0 Aqua -r r ------- WO 2013/103318 PCT/SE2013/050005 24 *Aqua. Pur. is added q.s. to achieve a dry content suitable for the coating process parameter setting to be applied, e g 24% w/w. Example 6 Manufacturing method as per Example 1, 5 Components of the tablet core as per Example 4. Film coating of the tablets can be performed using e g a standard modern pan coater equipped inter alia with air atomized spray nozzles to distribute the film coating fluid and a perforated drum of appropriate size. The film solution is prepared by adding the hydroxypropyl methylcellulose to aqua purificata whilst stirring. The film solution is 10 cooled to approximately 20*C and sucralose and acesulfame K is added when the solution is approximately 40'C. The solution is allowed to settle at ambient conditions for at least 3 hours where after the solution is homogenized using a Silverson homogenisator Thereafter flavor mixture is added containing Polyoxyethylene (80) sorbitan monooleate and mint flavor. The resulting mixture is stirred until it is 15 homogenous. Table 6B: Components of the film coating. gdients Percent mg/portion Hydroxypropy methy ce 1u ose 70 24.3 Titan dioxide ____3 1.05 Propylene glycol ___9 3 15 Polvoxyethvlene (80) sorbitan ronooleate 0 1 0 035 Aspartame 4.9 1 15 Acesulfame Potassium 3 105 vMint flavor 1 3 5 Sum "Dry" Exipients 100 35 ------------------------------- ----- l------------- Aguapur*................q * Aqua. Pur, is added q.s. to achieve a dry content suitable for the coating process parameter setting to be applied.
    WO 2013/103318 PCT/SE2013/050005 25 E xample 7 As per Example 6, but with the following film coating composition' Table 78: Components of the film coating. Ingredients Percent (w/w mg/portion jHydrxypropylmrethy cellulose 77 311.595 ~Titan dioxide __3 0.45 Polyethyleneqgycol 400 1 5 0.225 Sodium lauryl sulfate- 0 3 0045 Aspgrtame 4 ,3 Acesulfame Potassium 3 0,45 Mint flavor.. 1 ......
    5. ... 1 .. 1. Sum "Dry" Exipients.. 0 1 Aqua pur* * Aqua. Pur. is added q.s. to achieve a dry content suitable for the coating process 5 parameter setting to be applied. Example 8 Manufacturing method as per Example 1 Coating as per Example 4. Table 8A: Components of the tablet core Ingredients Percent(w/w) mg/port on [Nicotine resin complex (20% nicotine) 1.25 75 Mannitol .93 .. 98 . 5Zin Acetate dihydrate** 067 1402 Sodium carbonate 0.5 3 Mint flavor 1 6 Cooing as p ent Exml 10 Magjnesiumn stearate ___2.5 15 TOTAL 100 ~ 600 10 * EquivaIIIOale to 40m nef nicotine base. If nicotine resin complex with otherdegree of nicotine loading is used e g 15%5 then the amount of polyol is adjusted accordingly. ** Equivalent to 2.0 mg dose of zinc.
    WO 2013/103318 PCT/SE2013/050005 26 Example 9 Manufacturing method of tablet core as per Example 1, but with 6 mm round punches. Table 9A: Components of the tablet core, Ingredients Percent (w/w) mg/portion ............ Nicotine resin complex(20% nicotine Mannitol 72 25 72.25 2-Pyrrolidinone, 1-Etheny Hornopolymer (PVP) 18 18 ."odium carbonate ay25 MOint flavor _______I . . . . . Marnesium stearate 1 1.75 TOTAL 100 [ 100 * Equivalent to 1.5 mg dose of nicotine base 5 Coating manufacturing process as per Example IC. Table 9B: Components of the film coating. .. . . . .......... ..-. -......... "I,"-----.. ........... . Ingredients Percent (w/w) Img/portion Hydroxypropyl methylcellIu lose 76.8 7.68 sorbitan monooleate 0.2 0.02 Aspartame _4 0A Aces ulfame potassium _____ 1 4 04A ruit____ 1 um "Dy E iie __ ___ __ ___101 .Aua pur.._...... ...... . ........... * Aqua. Pur. is added q.s. to achieve a dry content suitable for the coating process parameter setting to be applied. A coloring component may also be included, e g titanium dioxide. 10 Example 10 Manufacturing method WO 2013/103318 PCT/SE2013/050005 27 The compositions for two tablet cores are given below in Table 10A. The master granule materials are sieved using an oscillating sieve with 1 mm mesh size and thereafter blended, according to methods known in the art e.g. using a double cone blender for 10 to 30 minutes. The blended materials are then wetted with purified water. 5 The wet mass is then fed to an extruder to form the granules. The resultant granules are dried using any method known in the art, such as fluid bed drying. The master granules are then screened for a suitable particle size, typically 75 pm, 200 mesh. The master granules are then blended with the nicotine active, at least one buffering agent, flavorants and sweeteners. Upon mixing and screening a lubricant or glidant is added to 10 the mixture. The tablets are compressed to sufficient hardness to enable an acceptable coating process and to achieve the desired in vivo dissolution time. Table 10 A Components of core. Ing1edients Formulation 10A Formulation 1B mg/portion mg/portion Master granule: Mannitol 175.8 1034.9 Potassium hydrogencarbonate 0.45 2.80 Sodiurn carbonate 3 67 22.75 Sodium alginate 1030 63 70 Xanthan qum 1 99 1 25.............. Calcium polycarbophil 15 13317 Dry mied components Nicotine resin complex 22.22 22 22 Potassium hydrogencarbonate 0 58 Sodium carbonate anhydrous 4 63 20 Aspartame - 6.00..... Acesulfame Potassium 1 50 Mint flavor 21.25 1.2 Magnesium stearate 2.50 200 Total weight of tablet core mg 250 1200 --------------... ....... .------. ---. ------.-...........
    WO 2013/103318 PCT/SE2013/050005 28 Table 10 B: Components of film coating. Ingredients Ircent Formulation 10 A Formulation 10 B (w/w) mg/portion mg/portion Hydroxypropyl methylcellulose 4.83 23.19 Titan dioxide 3 0.19 0.90 IPolyethyleneglycol 400 1.5 0.094 0.45 Sodiumulfate 0019 0.09 .......... -.......... ------------- -- 1 4 7 Aspartame 4 9 147 AesulfIae Potassium 1 5 0.19 0.90 Mint flavor 10 3 300 Sum "Dry" Exipients 100 8.633 30 Aqua Pur* q.sL * Aqua. Pur. is added q.s. to achieve a dry content suitable for the coating process parameter setting to be applied. 5 The respective amounts in the two above formulations 10 A and 10 B may vary within an interval of +- 15 % (w/w), preferably within + - 5 % (w/w) without thereby deviating from the desired characteristics for the respective formulations. Results from a sensory study confirmed the surprising finding of reduction of 10 disturbing sensations. 16 study persons (healthy volunteers; 8 males and 8 females in age range 34 to 64 years, either smokers or NRT-users) completed the study and compared two nicotine lozenge 4 mg formulations; lozenge A, uncoated, with all of flavoring agents and sweeteners in the tablet core, lozenge B with an additional film coating. The additional film coating for lozenge B carried a portion of flavoring agents is and sweeteners, while corresponding amount was withdrawn from the lozenge core. Thus the total amount of flavoring agents and sweeteners was the same in both lozenges. The lozenge cores for both A and B had the same composition except for the amounts of flavoring and sweetening agents.
    WO 2013/103318 PCT/SE2013/050005 29 The result showed that rating of tingling/burning sensation differed to a great extent: 12 out of 16 participants gave the lowest score (almost no burning/tingling) on a five grade scale after 30 seconds of testing for formulation B while only 7 out of 16 participants gave the lowest score for formulation A. The effect of the film was persistent; 5 after the lozenge had completely dissolved 10 of 16 participants gave the lowest score for formulation B while 7 out of 16 gave the lowest score for formulation A. All study persons tested both formulations with at least 30 minutes between the tests. The scale used for tingling/ burning was a 5-point intensity scale,
    权利要求:
    Claims (26)
    [1] 3. Dosage form according to claim 1 or 2, c h a r a c t e r i z e d in that upon administration said nicotine is essentially absorbable by the mucosa of the oral cavity and/or by the mucosa of the pharynx.
    [2] 4. Dosage form according to any one of claims 1 to 3, c h a r a c t e r i z e d in 15 that the at least one film coating preferably has a thickness from 10 to 500 microns, more preferably from 20 to 250 microns, and most preferably from 30 to 150 microns and/or, the core preferably has a weight from 50 mg to 2000 mg, more preferably 20 from 90 mg to 1200 mg and/or the film coating preferably has a weight of from 1 % to 15 % of the weight of the core. 5, Dosage form according to any one of claims 1 to 4, c h a r a c t e r i z e d in that the organoleptically disturbing sensation/s is/are selected from the 25 group consisting of irritation, acridity, taste alteration and taste blocking, feelings of burning, astringing, bitterness and tingling, and off tastes such as sour, salty, metallic, soapy, musty, sulphurous, pungent, fatty and foul tastes, preferably irritation, burning and bitterness. WO 2013/103318 PCT/SE2013/050005 31
    [3] 6. Dosage form according to claim 5, c h a r a c t e r i z e d in that the organoleptically disturbing sensation/s is/are selected from the group consisting of irritation, acridity, feelings of burning, bitterness and tingling, off tastes such as sour, salty, metallic, soapy, fatty and foul tastes. 5 7, Dosage form according to any one of claims 1 to 6, c h a r a c t e r i z e d in that the one or more organoleptically disturbing sensations is/are induced by the nicotine.
    [4] 8- Dosage form according to any one of claims I to 7, c h a r a c t e r i z e d in that the nicotine is in a form selected from a group consisting of a nicotine 10 salt, the free base form of nicotine, a nicotine derivative, such as a nicotine cation exchanger, a nicotine inclusion complex, nicotine in any non-covalent binding, nicotine bound to zeolites, nicotine bound to cellulose including micro-crystalline cellulose, or starch micro-spheres and mixtures thereof.
    [5] 9. Dosage form according to any one of claims I to 8, c h a r a c t e r i z e d in 15 that the one or more organoleptically disturbing sensations is/are induced by one or more excipients of the dosage form.
    [6] 10. Dosage form according to any one of claims 1 to 9, c h a r a c t e r i z e d in that it is a lozenge, a sublingual tablet, a buccal tablet, an orally disintegrating tablet or any other tablet, whereby upon administration the 20 nicotine is capable of being completely dissolved in the oral cavity.
    [7] 11. Dosage form according to any one of claims 1 to 10, c h a r a c t e r i z e d in that the at least one component for reduction of one or more organoleptically disturbing sensations comprises or consists of one or more flavoring agents.
    [8] 12. Dosage form according to any one of claims 1 to 11, c h a r a c t e r i z e d in 25 that the at least one component for reduction of one or more organoleptically disturbing sensations comprises or consists of one or more sweeteners. WO 2013/103318 PCT/SE2013/050005 32
    [9] 13. Dosage form according to any one of claims 1 to 12, c h a r a c t e r i z e d in that the at least one component for reduction of one or more organoleptically disturbing sensations comprises or consists of one or more flavoring agents and one or more sweeteners. 5 14. Dosage form according to any one of claims 1 to 13, c h a r a c t e r i z e d in that the one or more film-forming polymers is/are selected from the group consisting of cellulose ethers, such as hydroxy propyl methyl cellulose (HPMC), methyl hydroxy ethyl cellulose (MHEC), hydroxy propyl cellulose (HPC), hydroxyethyl cellulose (HEC), ethyl hydroxyl ethyl cellulose (EHEC), 10 and other film forming polymers, such as methacrylic acid copolymer-type C sodium carboxy methyl cellulose, polydextrose, polyethylene glycols, acrylate polymers, such as polyvinyl acrylate (PVA)), polyvinyl alcohol polyethylene glycol graft copolymers, complex of polyvinylpyrrolidone (PVP), such as povidone, polyvinyl alcohol, microcrystalline cellulose, carrageenan, is pregelatinized starch, polyethylene glycol, and combinations thereof.
    [10] 15. Dosage form according to claim 11 or 13, c h a r a c t e r i z e d in that the one or more flavoring agents are selected from the group consisting of natural or synthetic flavoring or aromatizing agents and may be added as 20 liquids and/or as powder, and that they may be selected from essential oils including distillations, solvent extractions, or cold expressions of chopped flowers, leaves, peel or pulped whole fruit comprising mixtures of alcohols, esters, aldehydes and lactones; essences including either diluted solutions of essential oils, or mixtures of synthetic chemicals blended to match the 25 natural flavor of the fruit, (e g strawberry, raspberry, black currant, banana, melon, cherry, passion fruit, pineapplee, peach, blackberry, mango, papaya, guava, cranberry, cloudberry, violet, pomegranate, pear, apple); artificial and natural flavors of brews and liquors, (e g cognac, whisky, rum, gin, sherry, port, and wine); tobacco, coffee, tea, cocoa, and mint; fruit juices including 30 expelled juice from washed, scrubbed fruits such as lemon, orange, and WO 2013/103318 PCT/SE2013/050005 33 lime and other citric fruits; spear mint, pepper mint, lemon balm, wintergreen; cinnamon, cacoe/cocoa, vanilla, liquorice, menthol, eucalyptus, aniseeds, nuts (e g peanuts, coconuts, hazelnuts, chestnuts, walnuts, colanuts), al monds, raisins and ginger: and powder and flour, and combinations thereof. 5 16. Dosage form according to claim 12 or 13, c h a r a c t e r i z e d in that the one or more sweeteners are selected from the group consisting of synthetic or natural sugars, i e any form of carbohydrates suitable for use as sweet ener, as well as so called artificial sweeteners such as saccharin, sodium saccharin, aspartame, acesulfame or Acesulfame K, potassium acesulfame, 10 thaumatin, glycyrrhizin, sucralose, dihydrochalcone, miraculin, monellin, stevside, neotame, N-substituted APM derivatives, cyclamic acid and its salts and alitame, the group consisting of sugar alcohols, such as sorbitol, xylitol, single sugars including sugars extracted from sugar cane and sugar beet (sucrose), dextrose (also called glucose), fructose (also called 15 leavulose), and lactose (also called milk sugar); sorbitol, mannitol, glycerol, xylitol, erythritol, maltitol syrup (or hydrogenated starch hydrolyzate), isomalt, lactitol; and mixtures of sugars including glucose syrup, (e g starch hydrolysates, containing a mixture of dextrose, maltose and a range of com plex sugars), invert sugar syrup, (e g sucrose inverted by invertase (also 20 called sucrase or sacchrase) containing a mixture of dextrose and fructose), high sugar content syrups such as treacle and honey containing a mixture of particular leavulose, dextrose, maltose, lactitole, sucrose, resins, dextrin and higher sugars; and malt or malt extracts, and combinations thereof.
    [11] 17. Dosage form according to claim 9, c h a r a c t e r i z e d in that the one or 2-5 more excipients encompass/es one or more buffers selected from the group consisting of carbonate (including bicarbonate or sesquicarbonate), glycinate, different phosphate systems such as trisodium phosphate, disodium hydrogen phosphate; and tripotassium phosphate, dipotassium hydrogen phosphate, glycerophosphate or citrate of an alkali metal (such as 30 potassium or sodium, or ammonium), e g trisodium and tripotassium citrate, WO 2013/103318 PCT/SE2013/050005 34 different hydroxides, amino acids, and mixtures thereof, and other excipients that may induce organoleptically disturbing sensations,
    [12] 18. Dosage form according to any preceding claim, c h a r a c t e r i z e d in that it further comprises 5 one or more plasticizers, such as glycerol, propylene glycol, polyethylene glycol (PEG 200-6000), organic esters such as triacetin (glyceryl triacetate), triethyl citrate, diethyl phtalate, dibutyl phtalate, dibutyl sebacete, acetyltriethyl citrate, acethyltributyl citrate, tributyl citrate and oils/glycerides, such as fractionated coconut oil, castor oil and distilled 10 acetylated monoglycerides, and/or one or more surfactants, such as polysorbates derived from PEG ylated sorbitan esterified with fatty acids such as Polysorbate 20 (Polyoxyethylene (20) sorbitan monolaurate), Polysorbate 40 (Polyoxyethylene (20) sorbitan monopalmitate), Polysorbate 60 15 (Polyoxyethylene (20) sorbitan monostearate), Polysorbate 80 (Polyoxyethylene (20) sorbitan monooleate) (e g Tween 80, Tween 40, Tween 20), sodium lauryl sulphate (SLS), poloxamer surfactants i.e. surfactants based on ethylene oxide - propylene oxide block copolymers and other surfactants with high HLB-value. 20 and/or one or more anti-tacking agents or glidants, such as talc, magnesium stearate, kaolin, colloidal silicon dioxide and glyceryl monostearate, and/or one or more coloring agents, and/or one or more opacifiers, and/or 25 one or more glossing agents, and/or one or more pore forming agents, and/or one or more excipient stabilizers and/or combinations thereof. WO 2013/103318 PCT/SE2013/050005 35
    [13] 19. Dosage form according to any one of claims 1 to 18, c h a r a c t e r i z e d in that the at least one film coating dissolves or disintegrates rapidly upon administration to the oral cavity, preferably in less than 2 minutes, more preferably in less than 1 minute and most preferably in less than 30 seconds, 5 from the moment of administration.
    [14] 20. Dosage form according to any one of claims 1 to 19, c h a r a c t e r i z e d in that said dosage form releases the nicotine within 30 minutes upon administration to the oral cavity, preferably within 20 minutes, from the moment of administration. 10 21. Dosage form according to any one of claims 1 to 20, c h a r a c t e r i z e d in that the reduction of one or more organoleptically disturbing sensations does not noticeably deteriorate the pharmaceutical effect of the nicotine and/or the API, 15 22. Dosage form according to any one of claims 1 to 21, c h a r a c t e r i z e d in that a unit dose thereof has a core comprising - nicotine in an amount corresponding to 0.5 mg to 12 mg nicotine base, - sorbitol 0 - 99.15 % (w/w), - xylitol 0 - 99.15 % (w/w), 20 - mannitol 0 - 99.15 % (w/w), - sodium bicarbonate 0 - 1.0 % (w/w), - sodium carbonate 0 - 1.0 % (w/w), - flavor 0.05 - 2.5 % (w/w), - high intensity sweetener or combination of 25 high intensity sweeteners 0 - 0.25 % (w/w), - magnesium stearate 0.5 - 2.5 % (wiw).
    [15] 23. Dosage form according to any one of claims 1 to 22, c h a r a c t e r i z e d in that the coating comprises WO 2013/103318 PCT/SE2013/050005 36 film-forming polymer around 80 % (w/w), surfactant around 0.3 % (w/w), high intensity sweetener or combination of high intensity sweeteners around 8 % (w/w), 5 flavor around 12 % (w/w).
    [16] 24. Dosage form according to any one of claims 1 to 22, c h a r a c t e r i z e d in that the coating comprises film-forming polymer around 80.5 % (w/w), 10 plasticizer around 8 % (w/w) surfactant 0.1 % (w/w), coloring component around 6 % (wiw) high intensity sweetener or combination of high intensity sweeteners around 4 % (w/w), 15 flavor around 1,25 % (w/w).
    [17] 25. Dosage form according to any one of claims 1 to 22, c h a r a c t e r i z e d in that the coating comprises film-forming polymer from around 44.5 to around 97.0 % (w/w), 20 plasticizer from 0 to around 25.0 % (w/w), surfactant from 0 to around 0.5 % (w/w), coloring component from 0 to around 10 % (w/w), high intensity sweetener or combination of high intensity sweeteners from around 0.5 to around 10 % (w/w), 25 flavor from around 2,5 to around 10 % (w/w).
    [18] 26. Dosage form according to any one of claims 1 to 21, c h a r a c t e r i z e d in that a unit dose comprises the below amounts in mg in the core and the coating respectively, whereby the respective amounts may vary within an WO 2013/103318 PCT/SE2013/050005 37 interval of +- 15 % (w/w), preferably within an interval of + - 5 % (w/w) Core 5 Potassu yroecronte04 Sodium carbonate 36 ... Sodimwealnate 1 Xanthan qurn 19-----------------... P50 Mint flavo-r 2 1.2 ...............- - . 2 .5 0------ -........ Magnesium s-tearuate ---- Coating Titan a dioxide 1 .1 :o 1 )y eeg (ol 4C0---------__ 0.094 Sodium~~~C la0y suft 19 Asprt ame 0.31 A cesul Ifarne Ponta ss ium 1 01 M int flavor -- 3----- ...........- . 00 20 27, Dosage form according to any one of claims 1 to 21, c h a r a c t e r i z e d in that a unit dose comprises the below amounts in mg in the core and the coating respectively, whereby the respective amounts may vary within an interval of +- 15 % (w/w), preferably within an interval of + - 5 % (w/w) 25 WO 2013/103318 PCT/SE2013/050005 38 Core MaW10 34.8 5 Potassium hy roge ncar bon ate 2. 8 0 --------- ....---- Smcabonate 2275 odium alginate 12.25 .alcium polyqa--bphil 317 iotine rsn complex 22.22 Aspart m e 6.00 ----- --------------- Mint flavor 1.2 Magnesium_ stearate 2.50 -- Total weight o)f tablet Core mg 100 10 Coating ------------------------- ------------------- Titan' dioxid'e109 P ovetyleeglcol40004 Sodium aur sulfe Aspartame 147 AceulfrnePotassium09 M in flv c 00r
    [19] 28. Dosage form according to any of claims 1 - 27 for treating a disease is selected from the group consisting of tobacco or nicotine dependence, Alzheimer's disease, Crohn's disease, Parkinson's disease, Tourette's syndrome, ulcerous colitis and post-smoking-cessation weight gain.
    [20] 29. Dosage form according to claim 28 wherein the medicament is for treating 20 tobacco or nicotine dependence.
    [21] 30. Dosage form according to any of claims 1 - 27 for use in therapy wherein the therapy is treatment of a disease selected from the group consisting of tobacco or nicotine dependence, Alzheimer's disease, Crohn's disease, WO 2013/103318 PCT/SE2013/050005 39 Parkinson's disease, Tourette's syndrome, ulcerous colitis and post smoking-cessation weight gain.
    [22] 31. Dosage form according to claim 30 for treating tobacco or nicotine 5 dependence.
    [23] 32. Therapy system comprising a dosage form according to any of claims I - 31 comprising nicotine in any form and any other dosage form for administration of nicotine. 10
    [24] 33. Method for medical treatment of a patient with a disease selected from the group consisting of tobacco or nicotine dependence, Alzheimer's disease, Crohn's disease, Parkinson's disease, Tourette's syndrome, ulcerous colitis and post-smoking-cessation weight gain, whereby a dosage form according 15 to any of claims 1 - 31 and/or a therapy system according to claim 32 is administered orally to the patient.
    [25] 34. Method according to claim 33 for the treatment of tobacco or nicotine dependence. 20
    [26] 35. Method according to claim 33 or 34 wherein the dosage form is retained in the oral cavity following administration to the patient such that the nicotine is absorbed by the mucosa of the oral cavity and/or by the mucosa of the pharynx. 25
    类似技术:
    公开号 | 公开日 | 专利标题
    CA2862497C|2020-04-14|Solid nicotine-comprising dosage form with reduced organoleptic disturbance
    KR101414063B1|2014-07-18|Coated pharmaceutical product for intraoral delivery of nicotine comprising trometamol as buffering agent
    CA2914379C|2021-03-23|Solid pharmaceutical dosage form for release of at least one active pharmaceutical ingredient in the oral cavity
    RU2291688C2|2007-01-20|Nicotine-containing chew with cover, method for its preparing and using
    AU2008251095B2|2013-01-31|Oral nicotine formulation buffered with amino acid
    ES2649268T5|2021-04-05|Pharmaceutical product for intraoral administration of nicotine comprising trometamol as a buffering agent
    US20080286341A1|2008-11-20|Buffered coated nicotine containing products
    同族专利:
    公开号 | 公开日
    PH12014501446A1|2014-10-08|
    MX370218B|2019-12-05|
    KR20140108728A|2014-09-12|
    HK1201448A1|2015-09-04|
    AU2013206983B2|2017-10-05|
    PH12014501446B1|2014-10-08|
    RU2014132174A|2016-02-27|
    BR112014016624A8|2017-07-04|
    EP2800557B1|2020-12-30|
    EP2800557A4|2015-09-09|
    AR089670A1|2014-09-10|
    CN104053433A|2014-09-17|
    JP6169609B2|2017-07-26|
    RU2623018C2|2017-06-21|
    NZ626672A|2016-11-25|
    CA2862497A1|2013-07-11|
    EP2800557A1|2014-11-12|
    KR102056041B1|2019-12-16|
    US20130177646A1|2013-07-11|
    DK2800557T3|2021-02-15|
    ES2848534T3|2021-08-10|
    MX2014008271A|2014-10-06|
    JP2015503581A|2015-02-02|
    WO2013103318A1|2013-07-11|
    PL2800557T3|2021-06-14|
    HUE053063T2|2021-06-28|
    ZA201405745B|2016-06-29|
    CA2862497C|2020-04-14|
    BR112014016624A2|2017-06-13|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    US1219291A|1910-12-13|1917-03-13|Chester Earl Gray|Process of manufacturing products from milk and cream.|
    GB2230439A|1989-04-20|1990-10-24|Alec Stanley Walter Shaw|Nicotine lozenges|
    US5549906A|1993-07-26|1996-08-27|Pharmacia Ab|Nicotine lozenge and therapeutic method for smoking cessation|
    US5362496A|1993-08-04|1994-11-08|Pharmetrix Corporation|Method and therapeutic system for smoking cessation|
    AU2891997A|1996-05-13|1997-12-05|Novartis Consumer Health S.A.|Buccal delivery system|
    US7815937B2|1998-10-27|2010-10-19|Biovail Laboratories International Srl|Quick dissolve compositions and tablets based thereon|
    US6583160B2|1999-04-14|2003-06-24|Steve Smith|Nicotine therapy method and oral carrier for assuaging tobacco-addiction|
    JP4044709B2|1999-11-19|2008-02-06|信越化学工業株式会社|Water-based film coating agent and oral solid preparation|
    US6419956B1|1999-12-30|2002-07-16|Ancile Pharmaceuticals|Odor-masking coating for a pharmaceutical preparation|
    US20020119196A1|2000-12-21|2002-08-29|Narendra Parikh|Texture masked particles containing an active ingredient|
    SE0102197D0|2001-06-20|2001-06-20|Pharmacia Ab|New product and use and manufacture thereof|
    WO2003003957A1|2001-07-06|2003-01-16|Lavipharm Laboratories Inc.|Quick dissolving oral mucosal drug delivery device with moisture barrier coating|
    JP5089840B2|2001-09-25|2012-12-05|救急薬品工業株式会社|Nicotine-containing film preparation|
    US20040037879A1|2001-11-02|2004-02-26|Adusumilli Prasad S.|Oral controlled release forms useful for reducing or preventing nicotine cravings|
    SG108299A1|2002-06-11|2005-01-28|Inst Data Storage|Method and apparatus for forming periodic structures|
    ES2708552T3|2002-12-20|2019-04-10|Niconovum Ab|Method for the preparation of a particulate material containing nicotine with a crystalline cellulose |
    US20040151771A1|2003-02-04|2004-08-05|Gin Jerry B.|Long-lasting, flavored dosage forms for sustained release of beneficial agents within the mouth|
    US7022750B2|2003-04-04|2006-04-04|Ppg Industries Ohio, Inc.|Anti-fouling coating containing copper and graphite|
    GB0320854D0|2003-09-05|2003-10-08|Arrow No 7 Ltd|Buccal drug delivery|
    US20070269492A1|2006-05-16|2007-11-22|Per Steen|New product and use and manufacture thereof|
    US20080286340A1|2007-05-16|2008-11-20|Sven-Borje Andersson|Buffered nicotine containing products|
    US20080286341A1|2007-05-16|2008-11-20|Sven-Borje Andersson|Buffered coated nicotine containing products|
    CN102036657A|2008-05-21|2011-04-27|诺瓦提斯公司|Tablettable chewing gums comprising nicotine and a buffering agent|
    CN102046021A|2008-05-26|2011-05-04|费尔廷制药公司|Film-coated compressed chewing gum|
    PT2361081T|2008-10-14|2016-09-05|Mcneil Ab|Multi portion intra-oral dosage form and use thereof|
    EP2233134A1|2009-03-27|2010-09-29|McNeil AB|Multi-portion intra-oral dosage form with organoleptic properties|
    US20100247586A1|2009-03-27|2010-09-30|Andreas Hugerth|Multi-Portion Intra-Oral Dosage Form With Organoleptic Properties|
    US20110268809A1|2010-04-28|2011-11-03|Paul Andrew Brinkley|Nicotine-Containing Pharmaceutical Compositions|JP6258920B2|2013-03-27|2018-01-10|Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社|Orally disintegrating film-coated tablets|
    CA2914379C|2013-06-03|2021-03-23|Mcneil Ab|Solid pharmaceutical dosage form for release of at least one active pharmaceutical ingredient in the oral cavity|
    WO2015068058A1|2013-11-06|2015-05-14|Rk Technology & Investments Pte. Ltd.|Tobacco free 'niconuts'and the process thereof|
    CN105828819A|2014-04-08|2016-08-03|桑萨（巴巴多斯）公司|Nicotine formulations and methods of making the same|
    CN104489916B|2014-12-02|2016-06-01|云南中烟工业有限责任公司|The application of red currant extract in cigarette|
    US9585835B1|2015-09-16|2017-03-07|Sansa CorporationInc.|Inhalable nicotine formulations and methods of making and using the same|
    US10149844B2|2015-09-16|2018-12-11|Philip Morris Products S.A.|Inhalable nicotine formulations, and methods of making and using thereof|
    AU2018273539A1|2017-05-22|2019-11-07|Johnson & Johnson Consumer Inc.|Lozenge dosage form|
    GB201811926D0|2018-07-20|2018-09-05|Nicoventures Trading Ltd|Aerosolisable formulation|
    SE2050532A1|2020-05-07|2021-11-08|Liw Innovation Ab|New compositions for oral or nasal use|
    法律状态:
    2018-02-01| FGA| Letters patent sealed or granted (standard patent)|
    优先权:
    申请号 | 申请日 | 专利标题
    SE1200017-0||2012-01-05||
    SE1200017||2012-01-05||
    PCT/SE2013/050005|WO2013103318A1|2012-01-05|2013-01-07|Solid nicotine-comprising dosage form with reduced organoleptic disturbance|
    [返回顶部]